AtriCure (NASDAQ:ATRC) said today that it commenced a public offering to issue and sell roughly $100 million worth of its common stock.
The Mason, Ohio–based company — maker of treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management — said it plans to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price less the underwriting discounts and commissions.
Net proceeds from the public offering will go toward working capital and other general corporate purposes, which may include repayment of debt or long-term liabilities and other potential corporate or market development activities.
